Krascendo 1
The first head-to-head trial among KRAS drugs: Roche's divarasib beat the two approved pills on progression and survival.
Roche announced (2 July 2026) that divarasib demonstrated superior PFS and OS versus sotorasib or adagrasib. Full data expected at a 2026 congress. Krascendo 2 tests divarasib + pembrolizumab first line.
Setting
Previously treated KRAS G12C NSCLC: divarasib vs sotorasib or adagrasib
Phase
Phase 3
Sponsor
Roche
Registry
Headline result
Superior PFS and OS vs approved G12C inhibitors (topline, July 2026).
Reported
2026
Enrolled
320
Replication
Topline reported July 2026; numbers pending presentation.
Pages like this
not linked directly; found by shared links- TrialKRYSTAL-12
Shares Adagrasib, KRAS, Non-small-cell lung cancer.
- TrialCodeBreaK 200
Shares Sotorasib, KRAS, Non-small-cell lung cancer.
- PersonKevan M. Shokat
Shares Adagrasib, Sotorasib, KRAS, Non-small-cell lung cancer.
- TermKRAS mutation subtypes (G12C, G12D, G12V)
Shares Adagrasib, Sotorasib, KRAS, Non-small-cell lung cancer.
- PersonPasi A. Jänne
Shares Adagrasib, KRAS, Non-small-cell lung cancer.
- Key paperOstrem and Shokat: the hidden pocket that made KRAS G12C druggable
Shares Adagrasib, Sotorasib, KRAS, Non-small-cell lung cancer.
- RoadmapKRAS roadmap: undruggable → G12C → pan-RAS
Shares Adagrasib, Sotorasib, KRAS, Non-small-cell lung cancer.
- IdeaCovalent chemistry for the RAS mutations that still have no drug